To be a European pharmaceutical manufacturer is to be prepared for uncertainty. However, it’s hard to imagine a more challenging energy landscape than the one at present.
And this was before recent geopolitical developments drove a further global surge in industrial energy costs, which were already, on average, more than double those in the United States and nearly 50% higher than in China.1
The energy trilemma
Regardless of how the market may shift, European pharmaceutical manufacturers still face what you might call an “energy trilemma,” a trifecta of key considerations that must be managed to stay competitive.
First, resilience is a critical challenge. The growing unreliability of grid infrastructure is beginning to affect European pharmaceutical manufacturers’ ability to rapidly ramp up new facilities before permanent system validation.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.